BPC-157 vs TB-500

Both are sold openly as research chemicals labeled not for human consumption, which is the legal fiction the research peptide market runs on. They are not legal for human use. Compounding pharmacies cannot make them for patients - BPC-157 and TB-500 hit FDA Category 2 in September 2023, meaning 503A compounding is prohibited. WADA also bans both for competitive athletes. The February 2026 FDA announcement flagged them for reclassification review, but status has not changed yet.

BPC-157 has more, though still very limited. Three small pilot studies in humans looking at gut healing and inflammatory bowel conditions, all underpowered and none placebo-controlled. TB-500 has zero human trials as an individual molecule. Its parent compound, thymosin beta-4, completed a Phase 2 wound-healing trial in 2009 that was never published. The animal literature for both is extensive, but translation from rodent to human is not guaranteed.

Commonly, yes. Forum protocols often combine 250-500mcg of BPC-157 twice daily with 2-2.5mg of TB-500 twice weekly, on the theory that BPC-157 handles local gut and tissue effects while TB-500 works systemically. There is no human trial evidence supporting the stack. The combined monthly cost runs $100-200. Doing so means doubling your unknown-unknowns rather than halving them.

Category 2 means the FDA has flagged a substance as having significant safety risks that make it inappropriate for 503A compounding pharmacies to produce. In practical terms it removed the main legal supply route that existed for BPC-157 and TB-500 in the US. It is a compounding restriction, not a full controlled-substance schedule, so possession is not criminalized federally. But no legitimate pharmacy can make it for you, and any seller claiming they can is lying or operating outside the law.

BPC-157 works via Synthetic peptide derived from gastric juice protein that promotes angiogenesis, modulates growth. TB-500 works via Synthetic version of thymosin beta-4 that promotes cell migration, reduces inflammation, and. They differ in FDA approval status, efficacy data, and cost.

BPC-157 typically costs $50 - $120/mo, while TB-500 costs $40 - $80/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.

BPC-157 is not FDA-approved (Category 2 (pending reclassification)). TB-500 is not FDA-approved (Category 2 (pending reclassification)). FDA approval indicates the treatment has met rigorous safety and efficacy standards.

Common side effects of BPC-157 include Injection site discomfort, Mild headache, Dizziness. Common side effects of TB-500 include Injection site reactions, Mild fatigue, Headache. Always consult a healthcare provider about potential side effects.

Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.